For the Inventor, By the Inventor

Enter assignee name

Genfit

USPTO Granted Patents = 72

% Expired Patents = 12.5

CIPO Patents = 6

EPO Patents = 34

Trademarks = 20

Forward Citations = 263

Loading Chart...

Loading Chart...

55 inventors (with patents filed for the assignee):

Robert Walczak (25 out of 25 patents)

Rémy Hanf (23 out of 23 patents)

Raphael Darteil (14 out of 14 patents)

4. Karine Caumont-Bertrand (13 out of 13 patents)

5. Carole Belanger (12 out of 12 patents)

6. Dean Hum (10 out of 10 patents)

7. Jean-Francois Delhomel (9 out of 9 patents)

8. Peggy Parroche (8 out of 8 patents)

9. Philippe Delataille (8 out of 8 patents)

10. Ingrid Dufour (8 out of 8 patents)

11. Zouher Majd (7 out of 7 patents)

12. Benoît Noel (7 out of 7 patents)

13. Enrico Perspicace (6 out of 6 patents)

14. Corinne Foucart (6 out of 6 patents)

15. Emilie Negro (6 out of 6 patents)

Core Competencies:

Cholestatic Diseases

Elafibranor

NASH Diagnosis

RORgamma Modulators

Combination Therapy

Fibrotic Diseases

1,3-Diphenylprop-2-en-1-one

Pharmaceutical Compositions

Non-Alcoholic Fatty Liver

Autoimmune Diseases

Histological Imaging

Patents

72 patents: Sort by Forward Citations

1. 12678427 - Combination therapy having antioxydant properties (2026-07-14),

2. 12673035 - Solid dosage forms of elafibranor (2026-07-07),

3. 12638460 - METHOD FOR NASH RISK ASSESSMENT (2026-05-26),

4. 12589086 - Compositions and methods for the treatment of primary biliary cholangitis (2026-03-31),

5. 12522564 - Polymorphs of elafibranor (2026-01-13),

6. 12458612 - Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists (2025-11-04),

7. 12391712 - Phosphate derivatives of RORgamma modulators and uses thereof (2025-08-19),

8. 12310935 - Methods of treatment of cholestatic diseases (2025-05-27),

9. 12303480 - Methods of treatment of cholestatic diseases (2025-05-20),

10. 12295928 - Methods of treatment of cholestatic diseases (2025-05-13),

11. 12295927 - Methods of treatment of cholestatic diseases (2025-05-13),

12. 12290498 - Methods of treatment of cholestatic diseases (2025-05-06),

13. 12233038 - Methods of treatment of cholestatic diseases (2025-02-25),

14. 12208087 - Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation (2025-01-28),

15. 12104209 - Non-invasive diagnostic of non-alcoholic steatohepatitis (2024-10-01),

Company Overview

Genfit is a biopharmaceutical company based in Loos, France, specializing in the development of innovative therapies for liver diseases. The organization focuses on cholestatic diseases and non-alcoholic steatohepatitis (NASH), leveraging advanced technologies such as RORgamma modulators and combination therapies. Genfit's research encompasses a range of pharmaceutical compositions aimed at addressing fibrotic diseases, with a commitment to improving patient outcomes through targeted treatment solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

72 Patents

#1 in Loos

#360 in France

#10,392 in the World

Genfit

Forward Citations = 263

55 inventors:

Robert Walczak (25 out of 25 patents)

Rémy Hanf (23 out of 23 patents)

Raphael Darteil (14 out of 14 patents)

4. Karine Caumont-Bertrand (13 out of 13 patents)

5. Carole Belanger (12 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genfit. Retrieved from https://idiyas.com/company/genfit

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…